The lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lupus Hub cannot guarantee the accuracy of translated content. The lupus and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lupus content recommended for you
During the 13th European Lupus Meeting, the Lupus Hub was pleased to speak to Jill Buyon, New York University, New York, US. We asked, What do healthcare professionals need to know about neonatal lupus?
What do HCPs need to know about neonatal lupus?
Jill Buyon opens by discussing the incidence of anti-Ro and anti-La antibodies in pregnancy and the likelihood of this resulting in neonatal lupus, with a focus on congenital heart block as an indicator. Buyon goes on to outline the importance of early detection and tailored treatment plans depending on the nature of the cardiovascular presentation and concludes by highlighting the potential for future at-home monitoring techniques.